DNA- and RNA-aptamers binding the soluble interleukin-6-receptor
The invention concerns DNA- and RNA-aptamers with high affinity and specificity for the human soluble IL-6-receptor with no or very low immunogenicity. These aptamers are very promising substances to treat or prevent diseases involving the IL-6-receptor, such as inflammation, cancer or infections. Furthermore, they can be easily and cost-efficiently produced and stored.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
New regulator of eating behaviour identified
The rapidly escalating prevalence of overweight and obesity poses a significant medical challenge worldwide. In addition to people’s changing lifestyles, genetic factors also play a key role in the development…
Harnessing Machine Learning for Breakthroughs with High-Power Lasers
A team of international scientists from Lawrence Livermore National Laboratory (LLNL), Fraunhofer Institute for Laser Technology ILT, and the Extreme Light Infrastructure (ELI) collaborated on an experiment to optimise high-intensity…
AI – Avalanche Intelligence at the SLF
Machine-trained algorithms assess the current avalanche situation in a similar way to humans – with different approaches, strengths and weaknesses. This text has been translated automatically. Forecast for Saturday, February…
